Does higher EPHX2 activity shorten protective epoxide signaling?

The EPHX2 gene plays a critical role in cardiovascular and inflammatory homeostasis by regulating bioactive lipid mediators.

Mechanistic pathways of epoxide degradation

• Enzymatic hydrolysis: EPHX2 encodes soluble epoxide hydrolase (sEH), an enzyme responsible for degrading protective epoxyeicosatrienoic acids (EETs).
• Metabolic conversion: sEH rapidly converts these active EETs into dihydroxyeicosatrienoic acids (DHETs) via epoxide hydrolysis, significantly reducing their biological activity.
• Signaling termination: Higher sEH activity accelerates the clearance of EETs, shortening the duration and magnitude of protective, epoxide-mediated signaling cascades.

Clinical and physiological implications

• Vascular function: EETs act as potent endogenous vasodilators and anti-inflammatory mediators. Their rapid degradation by sEH promotes vasoconstriction, vascular resistance, and inflammatory states.
• Genetic variants: The EPHX2 K55R gain-of-function variant increases sEH activity, which is clinically linked to reduced forearm blood flow, increased vascular resistance, and an elevated risk of coronary heart disease.
• Cardioprotection: Conversely, the EPHX2 R287Q loss-of-function variant decreases hydrolase activity, preserving protective EET levels and correlating with lower baseline blood pressure and enhanced vasodilatory capacity.

Bottom line

• Soluble epoxide hydrolase encoded by EPHX2 acts as a metabolic switch that degrades protective, anti-inflammatory, and vasodilatory EETs. Higher sEH activity actively limits beneficial epoxide signaling, whereas reducing its activity—either genetically or pharmacologically—helps preserve vascular function and control inflammation.